WEST

Freeform Search

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: l14 not l11

Display: 10 **Documents in Display Format:** CIT **Starting with Number** 1

Generate: ○ Hit List ◉ Hit Count ○ Image

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences

Search History

Today's Date: 5/10/2001

DB Name	Query	Hit Count	Set Name
USPT,PGPB,JPAB,EPAB,DWPI	l15 and mucus	0	L16
USPT,PGPB,JPAB,EPAB,DWPI	l14 not l11	52	L15
USPT,PGPB,JPAB,EPAB,DWPI	l13 and l5	71	L14
USPT,PGPB,JPAB,EPAB,DWPI	(l12) and (l1 or l2)	432	L13
USPT,PGPB,JPAB,EPAB,DWPI	cystic fibrosis or chronic bronchitis or bronchitis or bronchiectasis or bronchiolitis or bronchial asthma	13797	L12
USPT,PGPB,JPAB,EPAB,DWPI	l9 and l5	39	L11
USPT,PGPB,JPAB,EPAB,DWPI	(l1 or l2) and l3	1	L10
USPT,PGPB,JPAB,EPAB,DWPI	(l1 or l2) and l4	127	L9
USPT,PGPB,JPAB,EPAB,DWPI	l2 and l3	0	L8
USPT,PGPB	l2 and l3	0	L7
USPT	l2 and l3	0	L6
USPT	aerosol	40576	L5
USPT	viscoelasticity or mucus	4993	L4
USPT	viscoelasticity and mucus	29	L3
USPT	heparin sulfate or heparin sulphate or heparin phosphate	685	L2
USPT	dextran phosphate or dextran sulfate or dextran sulphate	4148	L1

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1619lxw
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 3	Feb 06	Engineering Information Encompass files have new names
NEWS 4	Feb 16	TOXLINE no longer being updated
NEWS 5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS 6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7	May 07	DGENE Reload

NEWS EXPRESS	April 18 CURRENT WINDOWS VERSION IS V6.0, CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP), AND CURRENT DISCOVER FILE IS DATED 04/06
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:25:29 ON 10 MAY 2001

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 11:25:36 ON 10 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 9 MAY 2001 HIGHEST RN 335078-44-9
DICTIONARY FILE UPDATES: 9 MAY 2001 HIGHEST RN 335078-44-9

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

```
=> s heparin

L1          652 HEPARIN

=> d


L1   ANSWER 1 OF 652  REGISTRY  COPYRIGHT 2001 ACS
RN   328594-43-0  REGISTRY
CN   DNA (human clone CF-686 cell surface heparin-binding protein
     fragment-specifying cDNA) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   98: PN: WO0116323 SEQID: 95 claimed DNA
FS   NUCLEIC ACID SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXLIT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1967 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


=> s dextran sulfate

         1067 DEXTRAN
        68131 SULFATE
L2         24 DEXTRAN SULFATE
              (DEXTRAN(W)SULFATE)

=> s dextran phosphate

         1067 DEXTRAN
       150283 PHOSPHATE
L3          7 DEXTRAN PHOSPHATE
              (DEXTRAN(W)PHOSPHATE)

=> d


L3   ANSWER 1 OF 7  REGISTRY  COPYRIGHT 2001 ACS
RN   174954-35-9  REGISTRY
CN   Vancomycin, compd. with dextran phosphate (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Dextran, phosphate, compd. with vancomycin (9CI)
FS   STEREOSEARCH
MF   C66 H75 Cl2 N9 O24 . x H3 O4 P . x Unspecified
SR   CA
LC   STN Files:   CA, CAPLUS, TOXLIT

     CM   1

     CRN  1404-90-6
     CMF  C66 H75 Cl2 N9 O24

Absolute stereochemistry.
```


OH
NHMe
Cl
H
N
R
R
R
Me
HO
S
S
O
S
S
O
Me
NH2
H
O
HO
R
S
S
O
S
R
O
HO
HO
O
O
HN
O
S
NH2
O
H
NH
R
O

—Bu-i



CM 2

CRN 9041-77-4
CMF H3 O4 P . x Unspecified

CM 3

CRN 9004-54-0
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 4

CRN 7664-38-2
CMF H3 O4 P



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	22.62	22.77

FILE 'STNGUIDE' ENTERED AT 11:26:46 ON 10 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 4, 2001 (20010504/UP).

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.00	22.77

FILE 'REGISTRY' ENTERED AT 11:31:33 ON 10 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 9 MAY 2001 HIGHEST RN 335078-44-9
DICTIONARY FILE UPDATES: 9 MAY 2001 HIGHEST RN 335078-44-9

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> fil caplus uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.31	23.08

FILE 'CAPLUS' ENTERED AT 11:32:08 ON 10 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:32:08 ON 10 MAY 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

(FILE 'HOME' ENTERED AT 11:25:29 ON 10 MAY 2001)

FILE 'REGISTRY' ENTERED AT 11:25:36 ON 10 MAY 2001
L1 652 S HEPARIN
L2 24 S DEXTRAN SULFATE
L3 7 S DEXTRAN PHOSPHATE

FILE 'STNGUIDE' ENTERED AT 11:26:46 ON 10 MAY 2001

FILE 'REGISTRY' ENTERED AT 11:31:33 ON 10 MAY 2001

FILE 'CAPLUS, USPATFULL' ENTERED AT 11:32:08 ON 10 MAY 2001

=> s l1 or l2 or l3

L4 58726 L1 OR L2 OR L3

=> s viscoelasticity and mucus

L5 90 VISCOELASTICITY AND MUCUS

=> s viscoelasticity or mucus

L6 27802 VISCOELASTICITY OR MUCUS

=> s l4 and l5

L7 3 L4 AND L5

=> d ibib abs

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:167786 CAPLUS
DOCUMENT NUMBER: 134:212736
TITLE: Pharmaceutical compositions of charged dextran as a mucoactive agent for treatment of respiratory disorders
INVENTOR(S): King, Malcolm
PATENT ASSIGNEE(S): Governors of the University of Alberta, Can.
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015672	A2	20010308	WO 2000-CA989	20000825

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-150605 P 19990826

AB The present invention is for a charged dextran, preferably dextran sulfate, as an improved mucoactive agent which can be used to improve **viscoelasticity** and clearance of respiratory tract **mucus**. The charged dextran can be used in the treatment of animals with impaired **mucus** clearance, **mucus** retention and/or **mucus** hypersecretion, such as cystic fibrosis, chronic bronchitis, bronchiectasis, bronchiolitis and bronchial asthma. Related methods of treatment and pharmaceutical compns., particularly aerosolized dextran sulfate compns. are encompassed within the scope of the invention. For example, delivery of aerosolized dextran sulfate to canine airways led to reduced **viscoelasticity** in improved clearability of the tracheal **mucus**.

=> d 2 ibib abs

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:528183 CAPLUS
DOCUMENT NUMBER: 133:359052
TITLE: Effects of dextran sulfate on tracheal mucociliary velocity in dogs
AUTHOR(S): Sudo, E.; Boyd, W. A.; King, M.
CORPORATE SOURCE: Pulmonary Research Group, University of Alberta, Edmonton, AB, Can.

SOURCE: J. Aerosol Med. (2000), 13(2), 87-96
CODEN: JAEMEP; ISSN: 0894-2684
PUBLISHER: Mary Ann Liebert, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have shown that low mol. wt. dextran, as a potential mucolytic agent, reduced the **viscoelasticity** and spinnability of cystic fibrosis (CF) sputum and improved its ciliary transportability in vitro; it also reduced **viscoelasticity** of healthy dog **mucus** in in vitro testing. In anesthetized dogs, dextran administered by aerosol at 65 mg/mL increased tracheal **mucus** velocity, but this increase was not sustained for higher concns. The purpose of the present study is to evaluate whether low mol. wt. dextran sulfate, a charged oligosaccharide, exhibits similar effects to previously tested neutral dextran when administered by aerosol to anesthetized dogs in terms of **mucus** rheol. and mucociliary clearance rate. Healthy mongrel dogs were anesthetized with pentobarbital and intubated. Aerosols of Ringer's soln. or dextran sulfate (m.w. 5000) dissolved in Ringer's were generated by Pari LC STAR nebulizer, and delivered during 30-min periods of spontaneous breathing. Tracheal transepithelial p.d. (PD, using agar filled electrodes) and tracheal mucociliary velocity (TMV, by charcoal marker particle transport) were measured under bronchoscopic control, and **mucus** for **viscoelasticity** anal. by magnetic rheometry was collected by the endotracheal tube method. We performed expts. in seven dogs, involving 30-min administrations of aerosol, sepd. by 30-min periods of no aerosol. All dogs received inhalations of 6.5 mg/mL, 20 mg/mL, and 65 mg/mL dextran sulfate. Tracheal **mucus** **viscoelasticity** (av. log G* over 1-100 rad/s) decreased progressively with increasing dose of dextran sulfate; for the highest concn. (65 mg/mL), log G* decreased by a factor of 2.61 ($p = 0.021$). A modest increase in the TMV was obsd. for the first dose of dextran sulfate (128% of baseline at 6.5 mg/mL, $p = 0.066$); thereafter TMV was stable. PD increased significantly at each concn. of dextran sulfate compared with Ringer control; however, there was no addnl. change between the three groups. The solids content of collected airway fluid (%SC) was gradually increased during successive 30-min dextran sulfate aerosols, indicating a significant residence time for the dextran in the **mucus**, and correlating with the decrease in **viscoelasticity**. These results suggest that dextran sulfate may be potentially of therapeutic value as a mucolytic agent, assisting **mucus** clearance by cough and physiotherapy, although whether it stimulates mucociliary clearance remains to be proven.

REFERENCE COUNT: 35
REFERENCE(S):
(5) Daviskas, E; Eur Respir J 1996, V9, P725 CAPLUS
(6) Daviskas, E; Eur Respir J 1997, V10, P2449 CAPLUS
(8) Feng, W; Pulm Pharmacol Ther 1999, V12, P35 CAPLUS
(14) King, M; Lung Biology in Health and Disease Series 1996, P391 CAPLUS
(20) Lorentsen, K; Ann Intern Med 1989, V111, P561 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 3 ibib abs

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:626027 CAPLUS
DOCUMENT NUMBER: 131:252572
TITLE: Use of glycosaminoglycan-degrading enzymes for management of airway-associated diseases
INVENTOR(S): Yacoby-Zeevi, Oron

PATENT ASSIGNEE(S): Insight Strategy & Marketing Ltd., Israel; Friedman, Mark M.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9948478	A1	19990930	WO 1999-US6189	19990322
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6153187	A	20001128	US 1998-46475	19980325
AU 9931077	A1	19991018	AU 1999-31077	19990322

PRIORITY APPLN. INFO.:
US 1998-46475 A 19980325
US 1997-922170 A2 19970902
WO 1999-US6189 W 19990322

AB A method of managing a patient having an accumulation of mucoid, mucopurulent, or purulent material contg. glycosaminoglycans comprises administering at least one glycosaminoglycan-degrading enzyme to the patient in an amt. therapeutically effective to reduce at least one of the following: the **viscoelasticity** of the material, pathogen infectivity, and inflammation. An article of manuf. is provided which comprises an inhaler including, as an active ingredient, at least one glycosaminoglycan-degrading enzyme for generating aerosols including the enzyme for management of a patient having an accumulation of mucoid, mucopurulent, or purulent material contg. glycosaminoglycans.

REFERENCE COUNT: 5
REFERENCE(S):
(1) Beth Israel Deaconess Medical Center Inc; WO 9846258 A2 1998 CAPLUS
(2) Fuks; US 5362641 A 1994 CAPLUS
(3) Ibex Technologies Inc; WO 9711684 A 1997 CAPLUS
(4) Kuna; US 5474983 A 1995 CAPLUS
(5) Rosen; US 5580862 A 1996 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 11:25:29 ON 10 MAY 2001)

FILE 'REGISTRY' ENTERED AT 11:25:36 ON 10 MAY 2001
L1 652 S HEPARIN
L2 24 S DEXTRAN SULFATE
L3 7 S DEXTRAN PHOSPHATE

FILE 'STNGUIDE' ENTERED AT 11:26:46 ON 10 MAY 2001

FILE 'REGISTRY' ENTERED AT 11:31:33 ON 10 MAY 2001

FILE 'CAPLUS, USPATFULL' ENTERED AT 11:32:08 ON 10 MAY 2001
L4 58726 S L1 OR L2 OR L3
L5 90 S VISCOELASTICITY AND MUCUS
L6 27802 S VISCOELASTICITY OR MUCUS
L7 3 S L4 AND L5

```
=> s (l4) and (cystic fibrosis or chronic bronchitis or bronchitis or
bronchiectasis or bronchiolitis or bronchial asthma)

L8         220 (L4) AND (CYSTIC FIBROSIS OR CHRONIC BRONCHITIS OR BRONCHITIS
               OR BRONCHIECTASIS OR BRONCHIOLITIS OR BRONCHIAL ASTHMA)

=> s l8 and aerosol

L9          23 L8 AND AEROSOL

=> s l8 and topical

L10         33 L8 AND TOPICAL

=> dup rem l9

PROCESSING COMPLETED FOR L9
L11         23 DUP REM L9 (0 DUPLICATES REMOVED)

=> dup rem l10

PROCESSING COMPLETED FOR L10
L12         31 DUP REM L10 (2 DUPLICATES REMOVED)

=> s l9 not l7

L13         20 L9 NOT L7

=> d l13 ibib abs


L13  ANSWER 1 OF 20  CAPLUS  COPYRIGHT 2001 ACS
ACCESSION NUMBER:         1997:557633  CAPLUS
DOCUMENT NUMBER:          127:239118
TITLE:                    Drug delivery systems containing ester sunscreens and
                          penetration enhancers
INVENTOR(S):              Reed, Barry Leonard; Morgan, Timothy Matthias;
Finnin,
                          Barrie Charles
PATENT ASSIGNEE(S):       Monash University, Australia; Reed, Barry Leonard;
                          Morgan, Timothy Matthias; Finnin, Barrie Charles
SOURCE:                   PCT Int. Appl., 70 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
     WO 9729735         A1   19970821       WO 1997-AU91      19970219
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,
             YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
             IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
             MR, NE, SN, TD, TG
     AU 9717134         A1   19970902       AU 1997-17134     19970219
     AU 706967          B2   19990701
     EP 901368          A1   19990317       EP 1997-904304    19970219
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
```

JP 2000504697	T2	20000418	JP 1997-528834	19970219
AU 9952589	A1	19991202	AU 1999-52589	19991001
PRIORITY APPLN. INFO.:			AU 1996-8144	19960219
			AU 1997-17134	19970219
			WO 1997-AU91	19970219

OTHER SOURCE(S): MARPAT 127:239118

AB A transdermal drug delivery system which comprises at least one physiol. active agent or prodrug thereof and at least one dermal penetration enhancer; characterized in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (1) an effective amt. of at least one physiol. active agent or prodrug thereof; (2) at least one non-volatile dermal penetration enhancer; and (3) at least one volatile liq.; characterized in that the dermal penetration enhancer is adapted to transport the physiol. active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liq. evaps., to form a reservoir or depot of a mixt. comprising the penetration enhancer and the physiol. active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal. The mean flux of 2% ketoprofen in 70% vol./vol. aq. ethanol through shed snakes kinetics in presence of 2% octyl salicylate in 70% vol./vol. aq. ethanol was 27.66 as compared to 2.58 .mu.g/cm2.h for azone. A transdermal **aerosol** contained 17.beta.-estradiol 2, octyl dimethyl-p-aminobenzoate 8, ethanol 69, and di-Me ether 30%.

=> d l13 ibib abs 2

L13 ANSWER 2 OF 20 USPATFULL

ACCESSION NUMBER:	2001:29111 USPATFULL
TITLE:	Pharmaceutical compositions for treating late phase allergic reactions and inflammatory diseases
INVENTOR(S):	Ahmed, Tahir, Coral Gables, FL, United States
PATENT ASSIGNEE(S):	Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6193957	20010227
APPLICATION INFO.:	US 1999-304814	19990504 (9)

RELATED APPLN. INFO.:	Division of Ser. No. US 1997-904565, filed on 4 Aug 1997, now patented, Pat. No. US 5980865 Continuation-in-part of Ser. No. US 1995-516786, filed on 18 Aug 1995, now patented, Pat. No. US 5690910
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Bawa, Raj
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.
NUMBER OF CLAIMS:	25
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 28 Drawing Page(s)
LINE COUNT:	1036

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating a mammalian patient suffering from or prone to a condition characterized by late phase allergic reactions, airway hyperresponsiveness or inflammatory reactions, e.g., asthma, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, inflammatory bowel disease or rheumatoid arthritis, comprising the administration to the patient of an oral, parenteral, intrabronchial, topical, intranasal or intraocular pharmaceutical composition containing in each dose about 0.005 to about 1.0 mg per kilogram of patient body weight of ultra-low molecular weight heparins (ULMWH) or other sulfated polysaccharides having average molecular weights of about 1,000-3,000 daltons. Suitable

inhalant and other pharmaceutical compositions for use in the novel treatment method are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 3

L13 ANSWER 3 OF 20 USPATFULL
ACCESSION NUMBER: 2000:160585 USPATFULL
TITLE: Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
INVENTOR(S): Yacoby-Zeevi, Oron, Meitar, Israel
PATENT ASSIGNEE(S): Insight Strategy & Marketing Ltd., Rohouot, Israel (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6153187	20001128
APPLICATION INFO.:	US 1998-46475	19980325 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-922170, filed on 2 Sep 1997, now patented, Pat. No. US 5968822
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Prouty, Rebecca E.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1041
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of managing a patient having an accumulation of mucoid, mucopurulent or purulent material containing glycosaminoglycans, the method comprising the step of administering at least one glycosaminoglycans degrading enzyme to the patient in an amount therapeutically effective to reduce at least one of the following: the visco-elasticity of the material, pathogens infectivity and inflammation. An article of manufacture comprising an inhaler including, as an active ingredient, at least one glycosaminoglycans degrading enzyme for generating aerosols including the enzyme for management a patient having an accumulation of mucoid, mucopurulent or purulent material containing glycosaminoglycans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 4

L13 ANSWER 4 OF 20 USPATFULL
ACCESSION NUMBER: 2000:77199 USPATFULL
TITLE: Method of synthesis of desulfated heparin and use thereof for inhibition of elastase and cathepsin
INVENTOR(S): Kennedy, Thomas P., Richmond, VA, United States
PATENT ASSIGNEE(S): Carolinas HealthCare System, Charlotte, NC, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6077683	20000620
APPLICATION INFO.:	US 1999-332820	19990614 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-865211, filed on 29 May 1997, now patented, Pat. No. US 5912237 which is a continuation-in-part of Ser. No. US 1994-191436, filed on 3 Feb 1994, now patented, Pat. No. US 5668118 which

is a continuation-in-part of Ser. No. US 1994-185069, filed on 21 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-919309, filed on 24 Jul 1992, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Leary, Louise N.
LEGAL REPRESENTATIVE: Alston & Bird LLP
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method and medicament for the inhibition of neutrophil elastase and cathepsin G in mammals comprising administering a treatment effective amount of 2-O-desulfated heparin to a mammal in need thereof. The medicament preferably is administered by aerosolization or by intravenous (IV) injection. Preferably, the 2-O-desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of
synthesizing 2-O-desulfated heparin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 5

L13 ANSWER 5 OF 20 USPATFULL
ACCESSION NUMBER: 2000:70428 USPATFULL
TITLE: Microparticles for lung delivery comprising diketopiperazine
INVENTOR(S): Steiner, Solomon S., Mt. Kisco, NY, United States
Feldstein, Robert, Dobbs Ferry, NY, United States
Lian, Huiling, Yonkers, NY, United States
Rhodes, Christopher A., Stamford, CT, United States
Shen, Gregory S., Hartsdale, NY, United States
PATENT ASSIGNEE(S): Pharmaceutical Discovery Corporation, Elmsford, NY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6071497	20000606
APPLICATION INFO.:	US 1997-847352	19970424 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-441378, filed on 15 May 1995
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Bawa, Raj
LEGAL REPRESENTATIVE: Arnall Golden & Gregory, LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 803
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Drug delivery to the pulmonary system has been achieved by encapsulation
of the drug to be delivered in microparticles having a size range between 0.5 and ten microns, preferably in the range of two to five microns, formed of a material releasing drug at a pH of greater than 6.4. In a preferred embodiment, the drug delivery system is based on the
formation of diketopiperazine microparticles which are stable at a pH of
6.4 or less and unstable at pH of greater than 6.4, or which are stable

at both acidic and basic pH, but which are unstable at pH between about 6.4 and 8. Other types of materials can also be used, including biodegradable natural and synthetic polymers, such as proteins, polymers of mixed amino acids (proteinoids), alginate, and poly(hydroxy acids). In another embodiment, the microparticles have been modified to effect targeting to specific cell types and to effect release only after reaching the targeted cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 6

L13 ANSWER 6 OF 20 USPATFULL

ACCESSION NUMBER:	1999:151200 USPATFULL	
TITLE:	Methods of treating asthma with o-desulfated heparin	
INVENTOR(S):	Kennedy, Thomas P., Richmond, VA, United States	
PATENT ASSIGNEE(S):	Cavalier Pharmaceuticals, Richmond, VA, United States (U.S. corporation)	
	NUMBER	DATE
PATENT INFORMATION:	US 5990097	19991123
APPLICATION INFO.:	US 1997-887989	19970703 (8)
	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24391	19960729 (60)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Henley, III, Raymond	
LEGAL REPRESENTATIVE:	Alston & Bird LLP	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 11 Drawing Page(s)	
LINE COUNT:	1456	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for reducing asthmatic response in a mammal comprising administering a response-reducing amount of O-desulfated heparin to the mammal, thereby reducing the asthmatic response. The amount can be administered by aerosolization. The O-desulfated heparin has O-desulfation at least at the 2-O and 3-O positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 6

L13 ANSWER 6 OF 20 USPATFULL

ACCESSION NUMBER:	1999:151200 USPATFULL	
TITLE:	Methods of treating asthma with o-desulfated heparin	
INVENTOR(S):	Kennedy, Thomas P., Richmond, VA, United States	
PATENT ASSIGNEE(S):	Cavalier Pharmaceuticals, Richmond, VA, United States (U.S. corporation)	
	NUMBER	DATE
PATENT INFORMATION:	US 5990097	19991123
APPLICATION INFO.:	US 1997-887989	19970703 (8)
	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24391	19960729 (60)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Henley, III, Raymond
LEGAL REPRESENTATIVE: Alston & Bird LLP
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for reducing asthmatic response in a mammal comprising administering a response-reducing amount of O-desulfated heparin to the mammal, thereby reducing the asthmatic response. The amount can be administered by aerosolization. The O-desulfated heparin has O-desulfation at least at the 2-O and 3-O positions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 7

L13 ANSWER 7 OF 20 USPATFULL
ACCESSION NUMBER: 1999:141272 USPATFULL
TITLE: Method for treating late phase allergic reactions and inflammatory diseases
INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States
PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5980865	19991109
APPLICATION INFO.:	US 1997-904565	19970804 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-516786, filed on 18 Aug 1995, now patented, Pat. No. US 5690910, issued on 25 Nov 1997
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Bawa, Raj
LEGAL REPRESENTATIVE: Kirschstein, et. al.
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Figure(s); 28 Drawing Page(s)
LINE COUNT: 1072
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating a mammalian patient suffering from or prone to a condition characterized by late phase allergic reactions, airway hyperresponsiveness or inflammatory reactions, e.g., asthma, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, inflammatory bowel disease or rheumatoid arthritis, comprising the administration to the patient of an oral, parenteral, intrabronchial, topical, intranasal or intraocular pharmaceutical composition containing in each dose about 0.005 to about 1.0 mg per kilogram of patient body weight of ultra-low molecular weight heparins (ULMWH) or other sulfated polysaccharides having average molecular weights of about 1,000-3,000 daltons. Suitable inhalant and other pharmaceutical compositions for use in the novel treatment method are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 8

L13 ANSWER 8 OF 20 USPATFULL
ACCESSION NUMBER: 1999:67256 USPATFULL
TITLE: Method of synthesis of desulfated heparin and use

thereof for inhibition of elastase and cathespin

INVENTOR(S): Kennedy, Thomas P., Richmond, VA, United States
PATENT ASSIGNEE(S): Carolinas HealthCare System, Charlotte, NC, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5912237	19990615
APPLICATION INFO.:	US 1997-865211	19970529 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-191436, filed on 3 Feb 1994, now patented, Pat. No. US 5668118 which is a continuation-in-part of Ser. No. US 1994-185069, filed on 21 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-919309, filed on 24 Jul 1992, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Lilling, Herbert J.
LEGAL REPRESENTATIVE: Alston & Bird LLP
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1242
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and medicament for the inhibition of neutrophil elastase and cathepsin G in mammals comprising administering a treatment effective amount of 2-O-desulfated heparin to a mammal in need thereof. The medicament preferably is administered by aerosolization or by intravenous (IV) injection. Preferably, the 2-O-desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O-desulfated heparin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 9

L13 ANSWER 9 OF 20 USPATFULL
ACCESSION NUMBER: 1999:63093 USPATFULL
TITLE: Treatment for diseases involving inflammation
INVENTOR(S): Tu, Yuan-Po, Everett, WA, United States
Irvin, Charles G., Englewood, CO, United States
PATENT ASSIGNEE(S): National Jewish Medical and Research Center, Denver, CO, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5908620	19990601
APPLICATION INFO.:	US 1997-943567	19971003 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-382099, filed on 31 Jan 1995, now patented, Pat. No. US 5674483, issued on 7 Oct 1997
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Achutamurthy, Ponnathapura
LEGAL REPRESENTATIVE: Sheridan Ross P.C.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 859
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method to protect an animal from a

disease involving inflammation by treating that animal with an effective
amount of IL-12. The present invention also relates to a method for prescribing treatment for a respiratory disease involving an inflammatory response and a method for monitoring the success of a treatment for a respiratory disease involving an inflammatory response in an animal. Also included in the present invention is a formulation comprising IL-12 and a compound capable of enhancing the effectiveness of the IL-12 at protecting an animal from a disease involving inflammation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 10

L13 ANSWER 10 OF 20 USPATFULL
ACCESSION NUMBER: 1999:61002 USPATFULL
TITLE: Treatment for diseases involving inflammation
INVENTOR(S): Tu, Yuan-Po, Everett, WA, United States
Irvin, Charles G., Englewood, CO, United States
PATENT ASSIGNEE(S): National Jewish Medical and Research Center, Denver, CO, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5906815	19990525
APPLICATION INFO.:	US 1997-943642	19971003 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-382099, filed on 31 Jan 1995, now patented, Pat. No. US 5674483, issued on 7 Oct 1997
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Achutamurthy, Ponnathapura
LEGAL REPRESENTATIVE: Sheridan Ross P.C.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 875
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method to protect an animal from a disease involving inflammation by treating that animal with an effective
amount of IL-12. The present invention also relates to a method for prescribing treatment for a respiratory disease involving an inflammatory response and a method for monitoring the success of a treatment for a respiratory disease involving an inflammatory response in an animal. Also included in the present invention is a formulation comprising IL-12 and a compound capable of enhancing the effectiveness of the IL-12 at protecting an animal from a disease involving inflammation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 11

L13 ANSWER 11 OF 20 USPATFULL
ACCESSION NUMBER: 1998:45226 USPATFULL
TITLE: Method for inhibiting angiogenesis
INVENTOR(S): Kohn, Elise C., Olney, MD, United States
Liotta, Lance A., Potomac, MD, United States
Alessandro, Riccardo, Bethesda, MD, United States
PATENT ASSIGNEE(S): United States of America, Washington, DC, United States

(U.S. government)

	NUMBER	DATE
PATENT INFORMATION:	US 5744492	19980428
APPLICATION INFO.:	US 1994-209651	19940310 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-123614, filed on 17 Sep 1993, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: MacMillan, Keith
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 775
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Angiogenesis is a composite of regulated proliferation and regulated invasion occuring in a variety of normal and pathologic conditions. Compound 1 and related analogs are useful for inhibiting angiogenesis in a host and offer a novel approach to the treatment of cancer, diabetic retinopathy, hemangiomata, vasculidities and other diseases associated with angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 12

L13 ANSWER 12 OF 20 USPATFULL
ACCESSION NUMBER: 1998:33606 USPATFULL
TITLE: Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
Matsunaga, Terry O., Tucson, AZ, United States
Yellowhair, David, Tucson, AZ, United States
PATENT ASSIGNEE(S): ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5733572	19980331
APPLICATION INFO.:	US 1994-346426	19941129 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-307305, filed on 16 Sep 1994 Ser. No. Ser. No. US 1993-159687, filed on 30 Nov 1993, now patented, Pat. No. US 5585112 Ser. No. Ser. No. US 1993-160232, filed on 30 Nov 1993, now patented, Pat. No. US 5542935 And Ser. No. US 1993-159674, filed on 30 Nov 1993, now abandoned , said Ser. No. US -159687 Ser. No. Ser. No. US -160232 And Ser. No. US -159674 , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1993-76239, filed on 11 Jun 1993, now patented, Pat. No. US 5469854 And Ser. No. US 1993-76250, filed on 11 Jun 1993, now patented, Pat. No. US 5580575 , said Ser. No. US -76239 And Ser. No. US -76250 , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-717084, filed on 18 Jun 1991, now patented, Pat. No. US 5228446 And Ser. No. US 1991-716899, filed on 18 Jun 1991, now abandoned , said Ser. No. US -717084 And Ser. No. US -716899 , each Ser. No. US - which

is a continuation-in-part of Ser. No. US 1990-569828, filed on 20 Aug 1990, now patented, Pat. No. US 5088499
which is a continuation-in-part of Ser. No. US 1989-455707, filed on 22 Dec 1989, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Kishore, Gollamudi S.
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 4174
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Gas and gaseous precursor filled microspheres, and foams thereof, provide novel topical and subcutaneous delivery vehicles for various active ingredients, including drugs and cosmetics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 13

L13 ANSWER 13 OF 20 USPATFULL
ACCESSION NUMBER: 1998:4573 USPATFULL
TITLE: Method of synthesis of 2-O-desulfated heparin and use thereof for inhibition of elastase and cathepsin G
INVENTOR(S): Kennedy, Thomas P., Richmond, VA, United States
PATENT ASSIGNEE(S): Cavalier Pharmaceuticals, Richmond, VA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5707974	19980113
APPLICATION INFO.:	US 1995-478199	19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-191436, filed on 3 Feb 1994 which is a continuation-in-part of Ser. No. US 1994-185069, filed on 21 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-919309, filed on 24 Jul 1992, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Lilling, Herbert J.
LEGAL REPRESENTATIVE: Needle & Rosenberg
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1205
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and medicament for the inhibition of neutrophil elastase and cathepsin G in mammals comprising administering a treatment effective amount of 2-O-desulfated heparin to a mammal in need thereof. The medicament preferably is administered by aerosolization or by intravenous (IV) injection. Preferably, the 2-O-desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O-desulfated heparin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 14

L13 ANSWER 14 OF 20 USPATFULL
ACCESSION NUMBER: 97:91156 USPATFULL
TITLE: Treatment for diseases involving inflammation
INVENTOR(S): Tu, Yuan-Po, Everett, WA, United States
Irvin, Charles G., Englewood, CO, United States
PATENT ASSIGNEE(S): National Jewish Medical and Research Center, Denver, CO, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5674483	19971007
APPLICATION INFO.:	US 1995-382099	19950131 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Achutamurthy, Ponnathapura
LEGAL REPRESENTATIVE: Sheridan Ross P.C.
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1025
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method to protect an animal from a disease involving inflammation by treating that animal with an effective amount of IL-12. The present invention also relates to a method for prescribing treatment for a respiratory disease involving an inflammatory response and a method for monitoring the success of a treatment for a respiratory disease involving an inflammatory response in an animal. Also included in the present invention is a formulation comprising IL-12 and a compound capable of enhancing the effectiveness of the IL-12 at protecting an animal from a disease involving inflammation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 1

L13 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:557633 CAPLUS
DOCUMENT NUMBER: 127:239118
TITLE: Drug delivery systems containing ester sunscreens and penetration enhancers
INVENTOR(S): Reed, Barry Leonard; Morgan, Timothy Matthias; Finnin, Barrie Charles
PATENT ASSIGNEE(S): Monash University, Australia; Reed, Barry Leonard; Morgan, Timothy Matthias; Finnin, Barrie Charles
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9729735	A1	19970821	WO 1997-AU91	19970219

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,

MR, NE, SN, TD, TG

AU 9717134	A1	19970902	AU 1997-17134	19970219
AU 706967	B2	19990701		
EP 901368	A1	19990317	EP 1997-904304	19970219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000504697	T2	20000418	JP 1997-528834	19970219
AU 9952589	A1	19991202	AU 1999-52589	19991001

PRIORITY APPLN. INFO.: AU 1996-8144 19960219
AU 1997-17134 19970219
WO 1997-AU91 19970219

OTHER SOURCE(S): MARPAT 127:239118

AB A transdermal drug delivery system which comprises at least one physiol. active agent or prodrug thereof and at least one dermal penetration enhancer; characterized in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (1) an effective amt. of at least one physiol. active agent or prodrug thereof; (2) at least one non-volatile dermal penetration enhancer; and (3) at least one volatile liq.; characterized in that the dermal penetration enhancer is adapted to transport the physiol. active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liq. evaps., to form a reservoir or depot of a mixt. comprising the penetration enhancer and the physiol. active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal. The mean flux of 2% ketoprofen in 70% vol./vol. aq. ethanol through shed snakes kinetics in presence of 2% octyl salicylate in 70% vol./vol. aq. ethanol was 27.66 as compared to 2.58 .mu.g/cm2.h for azone. A transdermal **aerosol** contained 17.beta.-estradiol 2, octyl dimethyl-p-aminobenzoate 8, ethanol 69, and di-Me ether 30%.

=> d l13 ibib abs 15

L13 ANSWER 15 OF 20 USPATFULL

ACCESSION NUMBER: 97:83945 USPATFULL

TITLE: Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G

INVENTOR(S): Kennedy, Thomas P., Richmond, VA, United States

PATENT ASSIGNEE(S): Cavalier Pharmaceuticals, Richmond, VA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5668118	19970916
APPLICATION INFO.:	US 1994-191436	19940203 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-185069, filed on 21 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-919309, filed on 24 Jul 1992, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Lilling, Herbert J.

LEGAL REPRESENTATIVE: Needle & Rosenberg

NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)

LINE COUNT: 1154

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and medicament for the inhibition of neutrophil elastase and cathepsin G in mammals comprising administering a treatment effective amount of 2-O-desulfated heparin to a mammal in need thereof. The medicament preferably is administered by aerosolization or by

intravenous (IV) injection. Preferably, the 2-O-desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of

synthesizing 2-O-desulfated heparin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 16

L13 ANSWER 16 OF 20 USPATFULL

ACCESSION NUMBER:	96:38888 USPATFULL
TITLE:	Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
INVENTOR(S):	Speert, David P., Vancouver, Canada Usher, Thomas C., Nassau, Bahamas
PATENT ASSIGNEE(S):	University of British Columbia, Vancouver, Canada (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5514665	19960507
APPLICATION INFO.:	US 1994-317228	19941003 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-175956, filed on 30 Dec 1993, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Griffin, Ronald W.	
LEGAL REPRESENTATIVE:	Choate, Hall & Stewart	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	623	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for reducing the risk of or preventing infections by bacterial pathogens in vivo. In particular, a method for reducing the risk of P. aeruginosa infection in vivo in compromised hosts such as **cystic fibrosis** patients. The methods involve the use of dextran or dextran sulphate as the active ingredient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 17

L13 ANSWER 17 OF 20 USPATFULL

ACCESSION NUMBER:	94:5678 USPATFULL
TITLE:	Purified forms of DNASE
INVENTOR(S):	Frenz, John, Millbrae, CA, United States Shire, Steven J., Belmont, CA, United States Sliwkowski, Mary B., San Carlos, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5279823	19940118
APPLICATION INFO.:	US 1992-895300	19920608 (7)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Wax, Robert A.	

ASSISTANT EXAMINER: Prouty, Rebecca
LEGAL REPRESENTATIVE: Johnston, Sean A.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1,2
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 957
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 18

L13 ANSWER 18 OF 20 USPATFULL
ACCESSION NUMBER: 91:62773 USPATFULL
TITLE: Medical application for heparin and related molecules
INVENTOR(S): Saliba, Jr., Michael J., 5582 Thunderbird La., La Jolla, CA, United States 92037

	NUMBER	DATE
PATENT INFORMATION:	US 5037810	19910806
APPLICATION INFO.:	US 1989-412403	19890926 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1987-27195, filed on 17 Mar 1987, now patented, Pat. No. US 4879282, issued on 7 Nov 1989
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Griffin, Ronald W.
ASSISTANT EXAMINER: Carson, Nancy S.
LEGAL REPRESENTATIVE: Brown, Martin Haller and McClain
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 875
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New uses for heparin, or heparin-like compounds are described that encompass preserving and healing of cells and cell functions arising from transplantations, circumcisions, dermatitides, fissures, fistulas, stimulation of epithelial growth, keloid prevention, cold injuries, pathology and forensic diagnosis, myocardium, trauma, decubitus ulcers, psoriasis, poisonings, insect and snake bites, corrosive ingestions, the "bends," space-travel sickness, brain and heart nerve conduction electrical dysrhythmias, pulmonary respiratory distress, blood and blood products, ulcerative colon lesions, interstitial cystitis, and related cosmetic uses. The uses are realized by applying the compounds either in solution, or in the for of a cream or **aerosol**, preferably at a pH of about 5.5, in an effective amount and for a time sufficient to effect treatment. Generally, the concentration of heparin or heparin-like compounds will be in the range of 1500 to 5000 international units per milliliter. Clinical assays are also described for determining the amount of heparin that should be used in those instances where the effective concentration is not known.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 19

L13 ANSWER 19 OF 20 USPATFULL
ACCESSION NUMBER: 90:5864 USPATFULL
TITLE: Method and apparatus for administering dehydrated liposomes by inhalation
INVENTOR(S): Radhakrishnan, Ramachandran, Fremont, CA, United States
Mihalko, Paul J., Fremont, CA, United States
Abra, Robert M., San Francisco, CA, United States
PATENT ASSIGNEE(S): Liposome Technology, Inc., Menlo Park, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4895719	19900123
APPLICATION INFO.:	US 1987-22937	19870306 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1985-737221, filed on 22 May 1985, now abandoned And Ser. No. US 1986-860528, filed on 7 May 1986, now abandoned And Ser. No. US 1986-937609, filed on 3 Dec 1986
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: Dehlinger, Peter J.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 972
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A system and method for administering a drug, at a selected dose, via the respiratory tract. Spray-dried liposome particles containing the selected dose of the entrapped drug are released into the air in aerosolized form, either by entrainment in an air or propellant stream, or by release from a pressurized can containing a suspension of the liposomes in a fluorchlorocarbon solvent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l13 ibib abs 20

L13 ANSWER 20 OF 20 USPATFULL
ACCESSION NUMBER: 89:90853 USPATFULL
TITLE: Medical application for heparin and related molecules
INVENTOR(S): Saliba, Jr., Michael J., 5582 Thunderbird La., La Jolla, CA, United States 92037

	NUMBER	DATE
PATENT INFORMATION:	US 4879282	19891107
APPLICATION INFO.:	US 1987-27195	19870317 (7)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Griffin, Ronald W.
ASSISTANT EXAMINER: Carson, Nancy S.
LEGAL REPRESENTATIVE: Brown, Martin, Haller & McClain
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 882
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New uses for heparin, or heparin-like compounds are described that encompass preserving and healing of cells and cell functions arising from transplantations, circumcisions, dermatitides, fissures, fistulas, stimulation of epithelial growth, keloid prevention, cold injuries, pathology and forensic diagnosis, myocardium, trauma, decubitus ulcers, psoriasis, poisonings, insect and snake bites, corrosive ingestions, the "bends," space-travel sickness, brain and heart nerve conduction electrical dysrhythmias, pulmonary respiratory distress, blood and blood products, ulcerative colon lesions, interstitial cystitis, and related cosmetic uses. The uses are realized by applying the compounds either in solution, or in the form of a cream or **aerosol**, preferably at a pH of about 5.5, in an effective amount and for a time sufficient to effect treatment. Generally, the concentration of heparin or heparin-like compounds will be in the range of 1500 to 5000 international units per milliliter. Clinical assays are also described for determining the amount of heparin that should be used in those instances where the effective concentration is not known.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 11:25:29 ON 10 MAY 2001)

FILE 'REGISTRY' ENTERED AT 11:25:36 ON 10 MAY 2001
L1 652 S HEPARIN
L2 24 S DEXTRAN SULFATE
L3 7 S DEXTRAN PHOSPHATE

FILE 'STNGUIDE' ENTERED AT 11:26:46 ON 10 MAY 2001

FILE 'REGISTRY' ENTERED AT 11:31:33 ON 10 MAY 2001

FILE 'CAPLUS, USPATFULL' ENTERED AT 11:32:08 ON 10 MAY 2001
L4 58726 S L1 OR L2 OR L3
L5 90 S VISCOELASTICITY AND MUCUS
L6 27802 S VISCOELASTICITY OR MUCUS
L7 3 S L4 AND L5
L8 220 S (L4) AND (CYSTIC FIBROSIS OR CHRONIC BRONCHITIS OR BRONCHITIS
L9 23 S L8 AND AEROSOL
L10 33 S L8 AND TOPICAL
L11 23 DUP REM L9 (0 DUPLICATES REMOVED)
L12 31 DUP REM L10 (2 DUPLICATES REMOVED)
L13 20 S L9 NOT L7

=> s l10 not l7

L14 33 L10 NOT L7

=> s l10 not l9

L15 23 L10 NOT L9

=> dup rem l15

PROCESSING COMPLETED FOR L15
L16 23 DUP REM L15 (0 DUPLICATES REMOVED)

=> d ibib abs

L16 ANSWER 1 OF 23 USPATFULL
ACCESSION NUMBER: 2001:25652 USPATFULL
TITLE: Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein
INVENTOR(S): Boyce, Frederick M., Belmont, MA, United States
Barsoum, James G., Lexington, MA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6190887	20010220
APPLICATION INFO.:	US 2000-514953	20000228 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-927317, filed on 11 Sep 1997
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Park, Hankyel
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox PLLC
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 38 Drawing Figure(s); 31 Drawing Page(s)
LINE COUNT: 2998
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods, nucleic acids, and cells for expressing an exogenous gene in a mammalian cell, involving introducing into the cell a non-mammalian DNA virus (e.g., a baculovirus) having an altered coat protein, the genome of which virus carries an exogenous gene, and growing the cell under conditions such that the gene is expressed. Also disclosed are methods for treating gene deficiency disorders, neurological disorders, or cancers in a mammal by (1) providing to a cell a therapeutically effective amount of a non-mammalian DNA virus having an altered coat protein, the genome of which virus carries an exogenous, therapeutic gene and (2) growing the cell under conditions such that the exogenous gene is expressed in the mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs2

'ABS2' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> d ibib abs 2

L16 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:756484 CAPLUS
DOCUMENT NUMBER: 133:329593
TITLE: Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
INVENTOR(S): Nyce, Jonathan W.

PATENT ASSIGNEE(S): East Carolina University, USA
SOURCE: PCT Int. Appl., 1592 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000062736	A2	20001026	WO 2000-US8020	20000324
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000006019	A	20010313	BR 2000-6019	20000324

PRIORITY APPLN. INFO.: US 1999-127958 P 19990406
WO 2000-US8020 W 20000324

OTHER SOURCE(S): MARPAT 133:329593

AB An in vivo method of selectively delivering a nucleic acid to a target gene or mRNA, comprises the **topical** administration, e.g. to the respiratory system, of a subject of a therapeutic amt. of an oligonucleotide (oligo) that is antisense to the initiation codon region, the coding region, the 5' or 3' intron-exon junctions or regions within 2 to 10 nucleotides of the junctions of the gene or antisense to a mRNA complementary to the gene in an amt. effective to reach the target polynucleotide and reducing or inhibiting expression. In addn. a method of treating an adenosine-mediated effect comprises topically administering to a subject an antisense oligo in an amt. effective to treat the respiratory, pulmonary, or airway disease. In order to minimize triggering adenosine receptors by their metab., the administered oligos have a low content of or are essentially free of adenosine. A pharmaceutical compn. and formulations comprise the oligo antisense to an adenosine receptor, genes and mRNAs encoding them, genomic and mRNA flanking regions, intron and exon borders and all regulatory and functionally related segments of the genes and mRNAs encoding the polypeptides, their salts and mixts. Various formulations contain a requisite carrier, and optionally other additives and biol. active agents.

The low-adenosine or adenosine-free (des-A) agent for practicing the method of the invention may be prepd. by selecting a target gene(s), genomic flanking region(s), RNA(s) and/or polypeptide(s) assocd. with a disease(s) or condition(s) afflicting lung airways, obtaining the sequence of the mRNA(s) corresponding to the target gene(s) and/or genomic flanking region(s), and/or RNAs encoding the target polypeptide(s), selecting at least one segment of the mRNA which may be up to 60 % free of thymidine (T) and synthesizing one or more anti-sense oligonucleotide(s) to the mRNA segments which are free of adenosine (A) by substituting a universal base for A when present in the oligonucleotide. The agent may be prepd. by selection of target nucleic acid sequences with GC running stretches, which have low T content, and by optionally replacing A in the antisense oligonucleotides with a "Universal or alternative base". The agent, compn. and formulations are used for prophylactic, preventive and therapeutic treatment of ailments assocd. with impaired respiration, lung allergy(ies) and/or inflammation and depletion lung surfactant or surfactant hypoprodn., such as pulmonary vasoconstriction, inflammation,

allergies, allergic rhinitis, asthma, impeded respiration, lung pain, **cystic fibrosis**, bronchoconstriction. The present treatment is suitable for administration in combination with other treatments, e.g. before, during and after other treatments, including radiation, chemotherapy, antibody therapy and surgery, among others. Alternatively, the present agent is effectively administered prophylactically or therapeutically by itself for conditions without known therapies or as a substitute for therapies exhibiting undesirable side effects. The treatment of this invention may be administered directly into the respiratory system of a subject so that the agent has direct access to the lungs, or by other effective routes of administration, e.g. topically, transdermally, by implantation, etc., in an amt. effective to reduce or inhibit the symptoms of the ailment.

=> d ibib abs 3

L16 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:534983 CAPLUS
DOCUMENT NUMBER: 133:140267
TITLE: A pharmaceutical composition of complex carbohydrates and essential oils
INVENTOR(S): Brown, Harold G.; Cooper, Carol A.; Hennessy, Kristina J.; Brown, Karen K.
PATENT ASSIGNEE(S): Dermal Research Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044367	A2	20000803	WO 2000-US2328	20000201
WO 2000044367	A3	20001221		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1999-117988 P 19990201
US 1999-127749 P 19990405
US 1999-137098 P 19990602
US 1999-142306 P 19990703
US 1999-166326 P 19991119

AB The invention discloses the discovery that a pharmaceutical compn. contg. complex carbohydrates with or without natural or synthetic essential oils can work effectively as a **topical**, oral or mucosal pharmaceutical compn. Such pharmaceutical compns. reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat **topical** bacterial infections such as acne and ulcers and prevent and treat numerous other conditions and diseases. Such pharmaceutical compns. can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromols. into the tissue of mammals and methods of blocking the adhesion, metastatic and coronary cascades. A 1.0% soln. of dermatan sulfate (chondroitin sulfate B) obtained was prepd. The

viscosity of this prepn. was <10 c/s. This prepn. was mixed 1:1 with the 1.0% wt/vol high mol. wt. hyaluronic acid soln. Five aliquots of 30 mL each were dispensed into vials. To the first aliquot was added 2.0% rosemary oil. To vials was added either eucalyptus oil, wintergreen oil or tea tree oil. No essential oils were added to the fifth vial. All prepns. were held at 40.degree. for 7 days after which they were evaluated for their suspension characteristics. Three patients with chronic pain/swelling complaints were given 1 vial of each prepn. All prepns. provided relief within 5 min and such relief lasted up to 6 h. Also, spreadability was totally acceptable to all patients.

=> d ibib abs 4

L16 ANSWER 4 OF 23 USPATFULL

ACCESSION NUMBER:	2000:164255 USPATFULL
TITLE:	Method for selective inactivation of viral replication
INVENTOR(S):	Miles, Vincent J., Chestnut Hill, MA, United States Mathews, Michael B., Montclair, NJ, United States Katze, Michael G., Seattle, WA, United States Watson, Julia C., San Jose, CA, United States Witherell, Gary, Orinda, CA, United States
PATENT ASSIGNEE(S):	Ribogene, Inc., Hayward, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6156496	20001205
APPLICATION INFO.:	US 1997-925156	19970908 (8)

RELATED APPLN. INFO.:	Division of Ser. No. US 1994-221816, filed on 1 Apr 1994, now patented, Pat. No. US 5738985 which is a continuation-in-part of Ser. No. US 1993-42024, filed on 2 Apr 1993, now abandoned
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Guzo, David
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT:	5525

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 5

L16 ANSWER 5 OF 23 USPATFULL

ACCESSION NUMBER:	2000:157000 USPATFULL
TITLE:	Human fibroblast diffusable factors
INVENTOR(S):	Mirzayans, Razmik, Edmonton, Canada Paterson, Malcolm C., Riyadh, Saudi Arabia
PATENT ASSIGNEE(S):	Alberta Cancer Board, Edmonton, Canada (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6149945	20001121
APPLICATION INFO.:	US 1997-910544	19970723 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-407883, filed on 20 Mar 1995, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Nashed, Nashaat T.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1746
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides for numerous cell factors involved in a novel cellular pathway that is activated in response to ionizing radiation. Several cell factor activities are described which either complement the radioresistant DNA synthesis phenotype of Ataxia Telangiectasia cells, or inhibit DNA synthesis in the cell. Other cell factor activities are described which inhibit mitosis by arresting the cell cycle prior to cell division. It is contemplated that compositions comprising the subject factors will be useful as both research tools, and as therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 6

L16 ANSWER 6 OF 23 USPATFULL
ACCESSION NUMBER: 2000:53757 USPATFULL
TITLE: Therapeutic liposome composition and method of preparation
INVENTOR(S): Allen, Theresa M., Edmonton, Canada
Uster, Paul, Tracy, CA, United States
Martin, Francis J., San Francisco, CA, United States
Zalipsky, Samuel, Redwood City, CA, United States
PATENT ASSIGNEE(S): Sequus Pharmaceuticals, Inc., Menlo Park, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6056973	20000502
APPLICATION INFO.:	US 1998-138480	19980821 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-949046, filed on 10 Oct 1997, now patented, Pat. No. US 5891468

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-28269	19961011 (60)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Kishore, Gollamudi S.
LEGAL REPRESENTATIVE: Mohr, Judy M.Dehlinger & Associates
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1210
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Reagents for use in preparing a therapeutic liposome composition sensitized to a target cell are described. The reagents include a liposomal composition composed of pre-formed liposomes having an entrapped therapeutic agent and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, target-cell sensitized liposome composition is formed by

incubating the liposomal composition with a selected conjugate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 7

L16 ANSWER 7 OF 23 USPATFULL
ACCESSION NUMBER: 2000:31403 USPATFULL
TITLE: Compositions containing nucleic acids and ligands for therapeutic treatment
INVENTOR(S): Baird, J. Andrew, San Diego, CA, United States
Chandler, Lois Ann, Encinitas, CA, United States
Sosnowski, Barbara A., Coronado, CA, United States
PATENT ASSIGNEE(S): Selective Genetics, Inc., La Jolla, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6037329	20000314
APPLICATION INFO.:	US 1996-718904	19960924 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-441979, filed on 16 May 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-213446, filed on 15 Mar 1994, now abandoned Ser. No. Ser. No. US 1994-213447, filed on 15 Mar 1994, now abandoned Ser. No. Ser. No. US 1994-297961, filed on 29 Aug 1994, now abandoned And Ser. No. US 1994-305771, filed on 13 Sep 1994, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Priebe, Scott D.
ASSISTANT EXAMINER: Nguyen, Dave Trong
LEGAL REPRESENTATIVE: Seed and Berry LLP
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Figure(s); 25 Drawing Page(s)
LINE COUNT: 7163
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 8

L16 ANSWER 8 OF 23 USPATFULL
ACCESSION NUMBER: 2000:27781 USPATFULL
TITLE: Integrative recombinant adenoviruses, preparation

thereof and therapeutical uses thereof

INVENTOR(S): Latta, Martine, Charenton le Pont, France
Denefle, Patrice, Saint Maur, France
Vigne, Emmanuelle, Ivry sur Seine, France
Perricaudet, Michel, Ecrosnes, France

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer S.A., Antony Cedex, France (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 6033885	20000307	
	WO 9523867	19950908	
APPLICATION INFO.:	US 1996-702573	19960912	(8)
	WO 1995-FR233	19950228	
		19960912	PCT 371 date
		19960912	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-2445	19940303

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Stucker, Jeffrey
ASSISTANT EXAMINER: Park, Honkyel
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 1115
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to recombinant adenoviruses having a cassette capable of integrating into the genome of infected cells, their preparation, pharmaceutical compositions containing them, and their use.

In particular, the cassette contains at least one inverted terminal repeat (ITR) Sequence from AAV and a heterologous DNA Sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	113.02	136.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.12	-4.12

STN INTERNATIONAL LOGOFF AT 11:47:10 ON 10 MAY 2001